Cancer gene mutation
Blurry Lines and the Cost Curve
27/03/12 01:54 Filed in: GenomeWeb Daily Scan
The New York Times featured an article focusing on Complete Genomics' efforts to offer cheaper sequencing through the combination of biology, chemistry, and computing, and mentions the stiff competition in the field. S. Pelech mentions the results of a completed detailed meta-analysis of all of the reported mutations in over 3000 human genes that have been linked with cancer in one way or another that was performed at Kinexus Bioinformatics Corporation out of curiosity to see what might be expected from random sequencing of cancer genomes. These studies revealed that the vast majority of these cancer genes feature mutations that are apparently randomly distributed throughout their entire sequences, and in most cases less than 1% of their amino acids have been observed to be altered with any cancer. Moreover, for more than half of these cancer-associated genes, either none or only 1 or 2 mutations were reported. Read More...